Heart Disease & Cardiology Clinical Trials Update: Week 14, 2026

Published April 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

The STOP-MED CTRCD Trial

This study is exploring whether it is safe for cancer survivors to stop taking heart failure medications once their heart function has returned to normal after cancer treatment. For patients who no longer need these medications, stopping them could reduce side effects and the burden of taking multiple pills every day. The trial is ongoing in various countries and includes patients who have finished cancer therapy and have no other reasons to keep using heart medications.

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

This large phase 3 trial is testing the drug pelacarsen to lower lipoprotein(a), a substance linked to higher heart risks, in people with existing cardiovascular disease. If the treatment is effective, it might become a new way to reduce serious heart problems like heart attacks and strokes for patients with high levels of lipoprotein(a). The study is active worldwide but not currently enrolling new participants.

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

This trial is investigating a new medication, maridebart cafraglutide, for adults living with heart failure and obesity, focusing on those whose heart pumping ability is preserved or only mildly reduced. The goal is to see if the drug can decrease hospital visits and improve symptoms. More than 5,000 participants around the world are involved, and the study is currently recruiting patients.

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

This research is testing a smartwatch-guided approach to blood thinning treatment for people with atrial fibrillation, a common heart rhythm problem. The method aims to reduce stroke risk while potentially requiring less continuous use of blood-thinning medication. The trial is recruiting in the United States and includes adults with different types of atrial fibrillation and moderate stroke risk.

Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent

This study is looking at whether personalized antiplatelet treatment after receiving drug-eluting stents can lower the risk of bleeding without increasing heart complications. It uses detailed imaging to guide treatment decisions. The trial is recruiting nearly 4,000 patients in South Korea and could lead to safer medication plans for people with coronary artery disease.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.